The California Department of Public Health’s (CDPH) efforts to crack down on direct-to-consumer (DTC) genetic testing in the state is prompting concern among many companies, even those who didn’t receive one of the 13 cease-and-desist letters that the agency sent out in June. Companies that received the letters include personal genomic startups 23andMe (Mountain View, Calif.) and Navigenics (Redwood Shores, Calif.). California appears to be following New York’s lead. Since last November, the New York State Department of Health has sent similar letters to 31 companies, notifying them that they needed to be licensed by the state in order to solicit DNA samples from New York residents.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

August 2008 - Table of Contents

LIR August 2008 (full PDF issue)

Medicare Bill Delivers 4.5% Lab Fee Update in 2009, Repeals Competitive Bidding Demo

Global M&A Market Totals Over $300 Million Through First Half of 2008

GE Healthcare Dives Into $2-$4 Billion Digital Pathology Market

John Muir’s Strategies for Outreach Growth Leads to $35 Million New Lab

Lakewood Pathology Enters $1 Billion GI Testing Market, Renamed PLUS Diagnostics

Calif. Cease-and-Desist Letters Spark Fear in DTC Testing Industry

Lab Stocks Continue to Show Strength; Index up 13% Over 13 Weeks

Nearly Half of Labs Struggle to Fill Med Tech Positions

Global M&A Market Totals Over $300 Million Through First Half of 2008